New antibody blocks malaria in trial
New antibody fully protects against malaria in trial, offering hope for high-risk regions.
Why it matters
- Could transform malaria prevention in high-risk regions.
- Offers potential for immediate, long-lasting protection with a single dose.
By the numbers
- 38 participants in the trial.
- 100% protection in highest dose group vs. 0% in placebo.
The big picture
- Could provide months of protection with a single dose, unlike vaccines.
- Testing in children in Uganda has begun.
What they're saying
- Lead researcher calls it a "fundamentally different way to stop infection."
- Co-author highlights it as a step forward for health equity.
Caveats
- Early-stage trial with small sample size.
What’s next
- Optimizing dosing and reducing costs for use in endemic regions.
- Trials in young children in Uganda underway.